Literature DB >> 16789637

Blood pressure in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Wolfgang Hoepffner1, Alexander Herrmann, Helmut Willgerodt, Eberhard Keller.   

Abstract

BACKGROUND: In patients with congenital adrenal hyperplasia (CAH) recording of blood pressure (BP) must be included in monitoring treatment to detect hypertension. AIM: To investigate the BP patterns in patients with CAH.
METHODS: Twenty-three children and adolescents (age 6-17 years) and 11 adult patients (age 18-26 years) were studied (21 females, 13 males; 28 salt-wasting patients). In the whole group BP in the outpatient clinic was compared with BP under hospitalisation and in 11 of the children and adolescents also with 24-hour ambulatory blood pressure monitoring (ABPM).
RESULTS: BP in the ward in children and adolescents but not in adults was significantly higher than BP in the outpatient clinic, where BP was in the upper normal range. There was also a significant difference between BP in the outpatient clinic and the lower ABPM in the 11 patients tested. Atrial natriuretic peptide (ANP) in blood serum showed normal values.
CONCLUSIONS: BP measured in outpatients in a relaxed and calm atmosphere meets the requirements for monitoring of treatment. Measurement of BP on the ward leads to falsely high results. ABPM is not necessary. Estimation of ANP provides no additional information.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16789637     DOI: 10.1515/jpem.2006.19.5.705

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  7 in total

Review 1.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

Review 2.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

3.  Cardiovascular Risk Factors in Children and Adolescents with Congenital Adrenal Hyperplasia.

Authors:  Elham Hashemi Dehkordi; Sara Khaheshi; Neda Mostofizadeh; Mahin Hashemipour
Journal:  Adv Biomed Res       Date:  2021-07-29

4.  Growth and reproductive outcomes in congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2010-02-01

5.  Metabolic profile and cardiovascular risk factors in adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Mouna Feki Mnif; Mahdi Kamoun; Fatma Mnif; Nadia Charfi; Basma Ben Naceur; Nozha Kallel; Nabila Rekik; Zainab Mnif; Mohamed Habib Sfar; Mohamed Tahar Sfar; Mongia Hachicha; Mohamed Abid
Journal:  Indian J Endocrinol Metab       Date:  2012-11

6.  Observation of hypertension in children with 21-hydroxylase deficiency: a preliminary report.

Authors:  Todd D Nebesio; Erica A Eugster
Journal:  Endocrine       Date:  2006-12       Impact factor: 3.925

7.  The relationship of carotid intima-media thickness with anthropometric and metabolic parameters in patients with classic congenital adrenal hyperplasia

Authors:  Hale Tuhan; Tülay Öztürk; Gönül Çatlı; Sezer Acar; Ayhan Abacı; Tuğba Egeli; Korcan Demir; Şule Can; Handan Güleryüz; Bumin Dündar; Ece Böber
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.